Background The number of obese pediatric patients requiring anesthesia is rapidly increasing. Although fentanyl is a commonly used narcotic during surgery, there are no pharmacokinetic (PK) data available for optimal dosing of fentanyl in adolescents with clinically severe obesity. Materials and Methods An institutional review board-approved exploratory pilot study was conducted in six adolescents aged 14-19 years undergoing bariatric surgery. Mean total body weight (TBW) and mean BMI were 137.4 ± 14.3 kg and 49.6 ± 6.4 kg/m 2 (99.5th BMI percentile), respectively. Fentanyl was administered intravenously for intraoperative analgesia based on ideal body weight per standard of care. PK blood samples were drawn over a 24-h post-dose period. Fentanyl PK parameters were calculated by non-compartmental analysis.
Introduction and Background
Obesity represents a rapidly growing public health issue across the globe. Because obesity is often accompanied by co-morbid diseases, pharmacotherapy, and/or surgical intervention may frequently be necessary.
Bariatric surgery is an option for carefully selected adolescents with clinically severe obesity who are unable to lose weight by conventional standards. Unfortunately, there is a lack of precision in the dosing of drugs for this special patient population. Moreover, the effective use of anesthetic medications during bariatric surgery is essential to ensure patient safety.
Fentanyl is a commonly used synthetic opioid used to manage moderate to severe pain in adolescent patients. It has a rapid onset and short duration of action. Fentanyl is mainly metabolized by cytochrome P450 3A (CYP3A) to norfentanyl [1] and shows dose-independent pharmacokinetics [2] . Fentanyl has been described as a high-extraction ratio drug and its elimination is dependent on hepatic blood flow [3] . All known metabolites of fentanyl are pharmacologically inactive and up to 76% of a single dose is excreted in the urine (approximately 6.5% remains unchanged) [4] .
Lipophilic drugs like fentanyl are primarily distributed into body fat, presumably resulting in an increased volume of distribution in obese patients. Different weight descriptors, for example, total body weight (TBW), ideal body weight (IBW), lean body weight (LBW), and/or pharmacokinetic mass (PKM), are currently being used to determine the required dose of fentanyl in obese patients [5, 6] . Dosing fentanyl based upon LBW or IBW may avoid overdosing and deleterious side effects such as postoperative respiratory depression.
The pharmacokinetics (PK) of fentanyl in adults has been well documented and shows a high inter-individual variability. Studies in infants and children have reported age-dependent differences in the PK and pharmacodynamic parameters of intravenous fentanyl with an enhanced clearance, particularly during the first years of life [7] [8] [9] [10] .
The purpose of this exploratory pilot study was to investigate the PK of fentanyl in adolescent patients with clinically severe obesity undergoing bariatric surgery.
Materials and Methods
This prospective, single-center pilot study was approved by the Institutional Review Board at Children's National Health System and was registered with clinicaltrials.gov (NCT01955993). Written informed consent and assent were obtained from all study participants or their parents (if applicable) before any study measures were initiated.
Study Population
Adolescent patients diagnosed with clinically severe obesity (body mass index [BMI] [99th percentile) between 14 and 19 years of age with an American Society of Anesthesiology (ASA) classification of I, II, or III were eligible for participation. Each patient received fentanyl per standard of care during the perioperative period. All patients were admitted to the hospital postoperatively for at least 24 h observation according to the surgical plan of care.
Exclusion criteria were pregnancy, lactation, hypersensitivity to any opioid, prior exposure to any opioid including fentanyl within a 24-h period, and treatment with inhibitors or inducers of cytochrome CYP3A within 2 weeks before inclusion.
Study Design and Procedures
After an overnight fast of at least 8 h, a peripheral intravenous catheter was placed in a forearm vein. If necessary, midazolam 2 mg (midazolam hydrochloride, Baxter, Deerfield, IL, USA) was administered for anxiolysis within 5 min before fentanyl. General anesthesia was induced using propofol (1-3 mg/kg of TBW; 1% emulsion, Fresenius Kabi, Lake Zurich, IL, USA), fentanyl (fentanyl citrate, Hospira, Lake Forest, IL, USA), and succinylcholine (1 mg/kg per TBW; succinylcholine chloride, Hospira), facilitating rapid and reliable intubation. General anesthesia was maintained with desflurane (Baxter) and rocuronium (rocuronium bromide, Fresenius Kabi) during the procedure. The induction dose of fentanyl was administered based on IBW (1-2 lg per kg IBW) using the formula [45.4 kg ? 0.89 9 (height in cm -152.4)] for female patients [5] . Using IBW for fentanyl dosing is the standard of care for obese patients undergoing bariatric anesthesia at our institution. Additional doses of fentanyl could be given if considered necessary by the responsible anesthesiologist.
A second peripheral intravenous catheter on the opposite forearm was inserted to facilitate adequate fluid hydration, and also used for blood sampling. Standard monitoring according to the ASA's guidelines was employed during general anesthesia, including noninvasive blood pressure measurements, 3-lead electrocardiogram, continuous pulse oximetry, and capnography.
Intraoperative pain management included intravenous acetaminophen (500-650 mg, Ofirmev Ò , acetaminophen, solution for injection, Cadence Pharmaceuticals, San Diego, CA, USA) and intravenous ketorolac (30 mg, ketorolac tromethamine, Fresenius Kabi) approximately 1 hour prior to extubation.
Perioperative intravenous antibiotics (cefazolin 2 g) and antiemetics (ondansetron 4-6 mg) were administered per routine management. Reversal of neuromuscular blockade was achieved with neostigmine and glycopyrrolate. Tracheal extubation occurred with each patient wide awake. Postoperative analgesia was provided by morphine 2 mg only as needed (morphine sulfate, Hospira), acetaminophen 500-650 mg (every 8 h), and ketorolac 30 mg (every 8 h), each prescribed around the clock and administered intravenously.
Clinical data were collected from the electronic medical record (Cerner Corporation, North Kansas City, MO, USA), including medical history, physical examination, pre-and post-operative laboratory studies, and perioperative administered medications.
Blood Sampling
Ten timed blood samples (1.5 mL each) were drawn into heparinized vacutainer tubes (BD Diagnostics, Franklin Lakes, NJ, USA) immediately before fentanyl injection at 5, 15, and 30 min as well as 1, 2, 4, 6, 12, and 24 h after fentanyl administration. If additional doses of fentanyl were required for pain management, blood samples of 1.5 mL were withdrawn before each fentanyl dosing. Plasma was separated from whole blood by centrifugation (2000g, 10 min at 4°C) and stored at -70°C until analysis.
Fentanyl Assay
Plasma concentrations of fentanyl were determined by validated assays as previously published [11] . The lower limit of quantification was 0.05 ng/mL (calibration range 0.05-10.0 ng/mL). Analytical bias, imprecision, and inaccuracy was \15%.
Pharmacokinetic and Statistical Analysis
Due to the exploratory nature of this study, no sample size calculation was performed. Pharmacokinetic parameters of fentanyl were calculated using noncompartmental analysis (Kinetica 5.0, ThermoFisher Scientific, Waltham, MA, USA). Apparent volume of distribution was calculated based on area under the curve. Previously established PK profiles in children [8, 10, 12] were used for comparison. Statistical analyses between groups were conducted using an unpaired t-test with Welch's correction (Prism 6.00, GraphPad Software Inc., La Jolla, CA, USA). A p-value \0.05 was considered to be significant.
Results

Study Population
Six female adolescent patients aged 14-19 years (mean 16.6 years) undergoing laparoscopic sleeve gastrectomy for treatment of their clinically severe obesity were included in this pilot study. Patient characteristics are provided in Table 1 . Total body weight ranged from 117.8 to 154.6 kg (mean 137.4 kg), ideal body weight ranged from 53.1 to 62.0 kg (mean 58.0 kg) and BMI ranged from 43.0 to 59.6 kg/m 2 (mean 49.6 kg/m 2 , 99.5th percentile). Ethnicities included three Caucasian patients, one African American, one Caucasian-Hispanic and one African American-Hispanic. Age and body weight were significantly different when compared with previously published pediatric control groups (see Table 1 ). All patients were assigned an ASA status of II or III.
Comorbidities included obstructive sleep apnea (OSA), polycystic ovarian syndrome, insulin resistance/diabetes mellitus type 2, hypertension, hypercholesterolemia, asthma and hypothyroidism, non-alcoholic steatohepatitis (NASH), gastroesophageal reflux, attention-deficit hyperactivity disorder, and depression.
Co-medications were levothyroxine (n = 1), metformin (n = 2), lisinopril (n = 1), amlodipine (n = 1), fluticasone (n = 1), salbutamol (n = 1), venlafaxine (n = 1), and lisdexamfetamine (n = 1). One patient had no medications. There were no known drug interactions between fentanyl and these compounds.
Pharmacokinetics of Fentanyl
Individual total fentanyl dosage ranged from 50 to 200 lg, resulting in a total fentanyl dose of 1.0 ± 0.4 lg/kg body weight. Fentanyl PK parameters are summarized in Table 1 . Fentanyl total body clearance was 1522 ± 310 mL/min, or 11.2 ± 2.6 mL/kg/min, when normalized to total body weight. Fentanyl volume of distribution was 635 ± 282 L, or 4.7 ± 2.1 L/kg, when normalized to weight. Both parameters are shown in Fig. 1 . Table 1 also shows previously assessed fentanyl pharmacokinetics in non-obese children as well as obese and lean adults for comparative purpose.
Efficacy
Five of the six studied patients needed additional opioids during their surgical procedure, whereas all six patients received acetaminophen and ketorolac during their postoperative recovery for pain control.
Safety
All patients underwent general anesthesia and laparoscopic surgery successfully without complications. Routine laboratory analyses had shown normal renal function in all patients and normal liver enzymes in all but one patient, who presented with elevated ALT and AST (within 29 of the upper limit of normal) and had been prediagnosed with metabolic syndrome. International normalized ratio (INR) and bilirubin were within normal ranges in all patients.
Discussion
Fentanyl Pharmacokinetics
This exploratory pilot study aimed to investigate the PK of fentanyl in a population of adolescents with clinically severe obesity. There is no doubt concerning normalweight age-matched controls representing an optimal comparison group for this study. However, since most surgeries in otherwise healthy adolescents in that age range are performed as outpatient procedures, it was not possible to obtain samples over 24 h from a sufficient number of healthy lean controls. In addition, the rates of childhood overweight and obesity are rising in the US [13] , resulting in an even smaller number of potentially recruitable normal-weight patients.
Nevertheless, even with the small number of obese patients in this pilot study, we could demonstrate that fentanyl total body clearance (in mL/min) is enhanced when compared with adult and pediatric data from the literature ( Table 1) . Obese patients who were otherwise healthy showed an increased circulating blood volume, not only due to an increase of the total blood volume, but also due to an increased cardiac output [14] . It has also been reported that splanchnic blood flow in obese patients is increased by up to 20% [14] .
Johnson et al. [10] studied the pharmacokinetics of fentanyl in children aged 10-14 years undergoing surgery (Table 1) . Reported absolute and normalized clearance values were clearly lower than those measured in our study, which may be due to the difference in body weight of these patients who received fentanyl over a 2-to 10-min infusion before undergoing surgery compared with our study cohort. While there was no relevant difference in elimination halflife, the significant difference in volume of distribution between the obese adolescents and the children studied by Johnson et al. could be attributed to the higher body fat mass in the obese adolescents. The extent of the volume of distribution, however, does not always correlate with the degree of lipophilicity of a drug [15] . Katz and Kelly [8] also found lower values than the current study (8.0 ± 3.9 mL/minÁkg vs 11.2 ± 2.6 mL/ minÁkg), even when expressed per kg bodyweight, though not statistically significant (p = 0.13), which may be due to the considerable variability in critically ill children receiving a continuous fentanyl infusion over 7-136 h. The patients' body weights were unfortunately not available for that study so the calculation of the absolute clearance was not possible. Assuming that the patients' body weights were within the normal range, their absolute fentanyl clearance would be lower than in our study. Freid et al. observed clearance values (mean ± SD 19.3 ± 12.4 mL/ kg/min) comparable to adult data in children aged 1 day to 10.9 years, but unfortunately the patients' age distribution and body weights were not specified [12] .
Other factors which may influence the calculation of fentanyl PK, especially its elimination half-life, are whether fentanyl was administered as a bolus dose (in our study) or continuous infusion, and the length of the blood sampling scheme. The dosing scheme was up to 10 h in the study by Johnson et al. [10] and 48 h post-infusion in the study by Katz and Kelly [8] compared with a period of 24 h in the present study. Additionally, in the study performed by Shibutani et al. investigating obese and lean adults [6] , blood specimens were not obtained using a timed sampling scheme. Instead, samples remaining from arterial blood gas analyses were analyzed for fentanyl at median 24.4 and 24.6 h after starting an infusion, respectively. The laboratory assay that was used for fentanyl quantification also accounts for inter-study variability. It is well known that cross-reactivity may occur with structurally related or matrix compounds when a radioimmunoassay is used, as was the case in the studies of Johnson et al. [10] , Katz and Kelly [8] , and Shibutani et al. [6] . In the present study, a liquid chromatography-mass spectrometry (LC-MS)/MS assay unambiguously identifying fentanyl was used [11] .
While 39 obese and 70 lean patients participated in the clinical trial of Shibutani et al. [6] , only pharmacokinetic data of 10 obese and 16 lean patients who received fentanyl infusions at constant doses also in the postoperative period were available. In addition, steady state was assumed when clearance was calculated. While the obese adults were significantly older than our study population, no significant difference was observed in total body weight (117.3 ± 33.4 kg vs 137.4 ± 14.3, p = 0.12) and fentanyl clearance calculated normalized to TBW (8.76 ± 1.74 mL/ minÁkg vs 11.2 ± 2.6 mL/minÁkg, p = 0.08), but was in absolute fentanyl clearance (986 ± 155 mL/min vs 1522 ± 310, p = 0.006). The calculated absolute fentanyl clearance was lower in lean adults (718 ± 163 mL/min) than in obese adults, with the sampling time point always being more than 12 h since start of the continuous infusion [6] .
When the data of Shibutani et al. [6] are compared with studies in healthy adults, the absolute clearance values of the lean adults (mean body weight 68.5 ± 9.5 kg) and the obese adults are lower than previously published data by (19.0 ± 6.8 mL/min/kg and 1388 ± 487 mL/min [20] , all data given as mean ± SD, if available). With the exception of the study by Palkama et al., if these data are compared with the present study (11.2 ± 2.6 mL/min/kg and 1522 ± 310 mL/min), the clearance of the adolescents with clinically severe obesity lies above the described ranges, when using absolute values (mL/min) for the total body clearance.
The values of the volume of distribution of fentanyl, for which no data were available in the study published by Shibutani et [20] , all data given as mean ± SD, if available). This might be due to the higher body fat mass in the adolescents with clinically severe obesity.
Factors Influencing Fentanyl Pharmacokinetics
It has been claimed that fentanyl is mainly metabolized to norfentanyl by CYP3A [1] . Fentanyl, however, is a highextraction-ratio drug whose metabolism is more dependent on hepatic blood flow than on enzymatic capacity [3] . Therefore, CYP3A4 seems not to be the major determinant of fentanyl total body clearance [20] .
Non-alcoholic fatty liver disease (NAFLD) may alter the expression of specific drug metabolizing enzymes and drug transporters [21] , which could influence the pharmacokinetics of drugs metabolized by the liver. The effect of fatty infiltration of the liver on pharmacokinetics is difficult to quantify since there can be large variations in liver texture and individual enzymatic performance [15] . While NAFLD results in increased fat deposition in the liver, leading to narrowing of the sinusoids and altering the liver morphology which may impact hepatic blood flow [22] , the latter does not necessarily need to be reduced since cardiac output as well as circulating blood volume, and thus, splanchnic blood flow, are increased in obese patients [3, 23] . Thus, a clear correlation between liver disease described by standard liver function tests, such as alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT), and impaired metabolic capacity regarding drugs could not be established to date [15] . In the present study, however, an alteration of PK by NAFLD seemed unlikely, especially because NAFLD is less often seen in obese adolescents compared with obese adults [24] . We therefore attribute the increased fentanyl clearance observed in our patient cohort to an increased hepatic blood flow as suggested previously.
Comparison of Weight Descriptors
Our current practice of dosing fentanyl based on IBW was adopted from standard adult bariatric anesthesia procedures since there are no peer-reviewed perioperative guidelines but only recommendations for fentanyl use in obese children and adolescents [25] . As dosing on TBW would overestimate the obese patients' fentanyl requirements with the potential for overdosing [26] , the decision to dose fentanyl based on IBW was implemented. Several authors suggested that fentanyl dose should be titrated according to clinical effect after initial LBW-based dosing [5, 26, 27] while Mulla et al. [28] and Adams and Murphy [14] suggested the use of a loading dose based on TBW and a maintenance dose based on LBW (or even body surface area), which had also been recommended for sufentanil [15, 29] . While this approach can be justified from a pharmacokinetic point of view based on the current study due to a similar volume of distribution per kg bodyweight and an increased clearance per kg bodyweight, the pharmacodynamics of fentanyl and thus the potential adverse effect of respiratory depression should not be omitted. The dosing scalar 'pharmacokinetic mass' had been introduced by Shibutani et al. [6] for fentanyl dosing in obese adults since fentanyl clearance seems to increase non-linearly with increasing body weight [30] . A recent review on anesthetic considerations for adolescent bariatric surgery recommended using LBW as dosing weight for fentanyl, up to a maximum of 100 kg LBW [31] .
Limitations of the Study
A limitation of the study is the small sample size, but due to the fact that no data on fentanyl PK was available in this particular patient group, we first aimed at conducting an exploratory pilot study.
Possible variations in fentanyl PK when compared with other studies may be caused by drug-drug interactions, since the patients received multiple medications. There were, however, no significant pharmacokinetic drug interactions documented in the summary of product characteristics between the medications taken by the study participants and fentanyl.
Differences in fentanyl clearance or volume of distribution between adolescents with clinically severe obesity and control groups of lean children [10] , as well as obese and lean adults, have been observed [6] that may be explained by neither the weight difference nor different study designs alone. Using historical control data as a comparison may introduce confounding errors. These errors may result from different study settings, such as surgical or intensive care units, changes in state-of-the-art techniques for general anesthesia like the use of new drug combinations, and perioperative pain management, as well as differences in the analytical methods used, assay sensitivity, and the methods of PK analysis.
Conclusion
This is the first study which focuses on the pharmacokinetics of fentanyl in adolescent patients with clinically severe obesity undergoing bariatric surgery. Compared with sparse previously published data, our results suggest that fentanyl clearance in obese adolescents with clinically severe obesity is enhanced. While the results of the current study yield that the loading dose of fentanyl may be based on TBW followed by maintenance doses based on LBW and IBW, we want to emphasize that clinically severely obese patients are more at risk for the respiratory side effects of fentanyl and the pharmacodynamics should also be taken into consideration when dosing fentanyl. Based on the present results, we suggest that our current practice of bolus dosing fentanyl based upon IBW during adolescent bariatric anesthesia may be appropriate in the absence of definitive pharmacodynamic assessments.
Further investigation is required including pharmacodynamic characterization to determine appropriate dosing of fentanyl in this unique patient population.
